• Gary P Kobinger, Joanita M Figueredo, Thomas Rowe, Yan Zhi, Guangping Gao, Julio C Sanmiguel, Peter Bell, Nelson A Wivel, Lois A Zitzow, Douglas B Flieder, Robert J Hogan, and James M Wilson.
• Special Pathogens Program, National Microbiology Laboratory, Health Canada, Canadian Science Centre for Human and Animal Health, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada.
• Vaccine. 2007 Jul 9; 25 (28): 5220-31.

AbstractA ferret model of severe acute respiratory syndrome (SARS)-CoV infection was used to evaluate the efficacy of an adenovirus vaccine. Animals were subjected to heterologous prime-boost using vectors from human serotype 5 and chimpanzee derived adenoviruses (human AdHu5 and chimpanzee AdC7) expressing spike protein followed by intranasal challenge with SARS-CoV. Vaccination led to a substantial reduction in viral load and prevented the severe pneumonia seen in unvaccinated animals. The same prime-boost strategy was effective in rhesus macaques in eliciting SARS-CoV specific immune responses. These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection.

37 keywords...

hide…